Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-07-24
2007-07-24
Winkler, Ulrike (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C435S006120, C435S007210, C435S069100, C435S320100, C514S04400A, C536S023720
Reexamination Certificate
active
10077027
ABSTRACT:
The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
REFERENCES:
patent: 5837464 (1998-11-01), Capon et al.
patent: 5939320 (1999-08-01), Littman et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 6406911 (2002-06-01), Dong
patent: WO 97/27319 (1997-01-01), None
patent: WO01/81608 (2001-04-01), None
Zhang et al. Primary Virus Envelope Cross-Reactivity of the Broadening Neutralizing Antibody Response during Early Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology (1999) vol. 73, No. 6, pp. 5225-5230.
Fang et al. Molecular cloning of full-length HIV-1 genomes directly from plasma viral RNA. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (1996) vol. 12, pp. 352-357.
International Search Report corresponding to PCT/US03/04373, Jul. 22, 2003, PCT.
Auewarakul et al., (2001), “Application of HIV-1-Green Fluorescent Protein (GFP) Reporter Viruses in Neutralizing Antibody Assays,”Asian Pacific Journal of Allergy and Immunology, 19:139-144.
Cho et al., (2001), “Polyvalent Envelope Glycoprotein Vaccine Elicits a Broader Neutralizing Antibody Response but is Unable to Provide Sterilizing Protection Against Heterologous Simian/Human Immunodeficiency Virus Infection in Pigtailed Macaques,”Journal of Virology, 75(5): 2224-2234.
Dorsky et al., (1996), “Detection of HIV-1 Infection with a Green Fluorescent Protein Reporter System,”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13:308-313.
Hioe, et al., (1997), “Resting Cell Neutralization Assay for HIV-1 Primary Isolates,”Methods: A Companion to Methods in Enzymol.12:300-305.
Montefiori, et al., (2001), “Neutralizing Antibodies Associated with Viremia Control in a Subset of Individuals after Treatment of Acute Human Immunodeficiency Virus Type I Infection,”Journal of Virology, 75(21): 10200-10207.
Rencher, et al., (1995), “Does the Key to a Successful HIV Type I Vaccine Lie among the Envelope Sequences of Infected Individuals?,”AIDS Research and Human Retroviruses, 11(9): 1131-1133.
Alkhatib et al., 1996, “CC CKR5: A Rantes, MIP-1alpha, MIP-1 Beta Receptor as a Fusion Cofactor for Macrophage-tropic Hiv-1,”Science, 272:1955-58.
Allaway et al., 1993, “Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-based Molecules in Combination with Antibodies to Gp120 or Gp41,”Aids Res. Hum. Retroviruses, 9:581-87.
Baba et al., 1999, “A Small-molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-hiv-1 Activity,”Proc. Natl. Acad. Sci. USA, 96:5698-03.
Barnes, W.M., 1994, “PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates,” Proc. Natl. Acad. Sci, USA 91, 2216-20.
Baxter et al., 1999, “A Pilot Study of the Short-term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (Gart) in Patients Failing Antiretroviral Therapy,”Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Il.
Bernard and Couturier, 1992, “Cell Killing by the F Plasmid Ccdb protein Involves Poisoning of DNAtopoisomerase II Complexes,” J. Mol. Bio. 226:735-45.
Bernard et al., 1993, “The F Plasmid CcdB protein Induces Efficient ATP-dependent Dna Cleavage by Gyrase,” J Mol. Biol. 23:534-41.
Bleul et al., 1996, “The Lymphocyte Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1 Entry,” Nature 382:829-33.
Bridger et al., 1999, “Synthesis and Structure-activity Relationships of Phenylenebis(methylene)-linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4,” J. Med. Chem. 42:3971-81.
Coffin, 1995, “HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy,” Science 267:483-489.
DHHS (Department of Health and Human Services), 2000, Henry Kaiser Family Foundation: “Guidelines for the Use of Antiretrovirals Agents in HIV-infected Adults and Adolescents.”
Dorn et al., 2001, “Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 1: Discovery and initial Structure-Activity Relationships for 1-Amino-2-phenyl-4-(piperidin-1-y1) butanes,” Bioorganic & Medicinal Chemistry Letters 11:259-64.
Finke et al., 2001, “Antagonist of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 4: Synthesis and Structure-Activity Relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl) butanes,” Bioorganic & Medicinal Chemistry Letters 11:2475-79.
Gao et al., 1996, “Molecular Cloning and Analysis of Functional Envelope Genes From Human Immunodeficiency Virus Type-1 Sequence Subtypes A through G,” Journal of Virology 70:1651-1667.
Gerdes et al., 1990, “The Hok Killer Gene Family in Gram-negative Bacteria,” The New Biologist: 2:946-56.
Grovit-Ferbas et al., 1998 “Potential Contribution of Viral Envelope and Hose Genetic Factors In Human Immunodeficiency Virus Type 1-Infected Long Term Survivor,” Journal of Virology 72:8650-8658.
Helseth et al., 1990 “Rapid Complementation Assays Measuring Replicative Potential Of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein Mutants,” Journal of Virology 64:2416-2420.
Hertogs et al., 1998, “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs,”Antimicrob. Agents Chemother. 42:269-76.
Hwang et al., 1997, “A Conditional Self-inactivating Retrovirus Vector That Uses a Tetracycline-responsive Expression System,” J. Virol. 71: 7128-31.
Japour et al., 1993, “Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinial Human Immunodeficiency Virus Type 1 Isolates,” Antimicrob. Agents Chemother. 37:1095-01.
Judice et al., 1997, “Inhibition HIV Type 1 Infectivity by Constrained Alphahelical Peptides: Implications for the Viral Fusion Mechanism,”Proc. Natl. Acad. Sci. U S A94:13426-30.
Kilby et al., 1998, “Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of Gp41-mediated Virus Entry,”Nat Med.4:1302-07.
Mascola et al., 2000, “HIV-1 Entry at the Mucosal Surface: Role of Antibodies in Protection,” AIDS, 14 (suppl 3): S167-174.
Mascola et al., 2000, “Protection of Macaques Against Vaginal Transmission of a Pathogenic HIV-1/siv Chimeric Virus by Passive Infusion of Neutralizing Antibodies,” Nature Med. 6:207-10.
Miy
Huang Wei
Little Susan
Parkin Neil T.
Petropoulos Christos J.
Richman Douglas
Jones Day
Monogram Biosciences, Inc.
Winkler Ulrike
LandOfFree
Method of evaluating a patient antibody response to envelope... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of evaluating a patient antibody response to envelope..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating a patient antibody response to envelope... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794633